Long-term outcomes after treatment for relapsed or refractory Ph+ ALL
Official title: Retrospective Study of the Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
Run by Group for Research in Adult Acute Lymphoblastic Leukemia · NCT07433400 · Data updated 2026-11-12
This project looks back at adults with relapsed or refractory Philadelphia chromosome–positive (Ph+) ALL to see which treatment and response patterns link to better long-term outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Group for Research in Adult Acute Lymphoblastic Leukemia Academic / other |
| Locations | 1 site (Pierre-Bénite) |
| Status | Recruiting |
| Started | August 29, 2025 |
| Main results expected | December 31, 2035 |
| Study ends | December 31, 2035 |
| Registry record updated | February 25, 2026 |
| Trial ID | NCT07433400 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with relapsed or refractory Ph+ ALL who were treated and followed at the participating GRAALL site(s).
✕Probably not a fit
Patients who are newly diagnosed, under 18, treated outside the GRAALL network, or who have incomplete medical records are unlikely to benefit from this retrospective analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective observational analysis reviews medical records of adults (≥18) with relapsed or refractory Ph+ ALL who were treated and monitored through the GRAALL network. Investigators will extract treatment details, use of tyrosine kinase inhibitors, response measures, and long-term progression and survival data. The team will analyze response profiles to identify patterns associated with longer remission or survival after relapse. No new treatments are given; the work uses existing clinical data to inform future therapeutic strategies.
Why it matters
Potential benefit: If successful, the findings could help clinicians tailor treatments to improve long-term remission and survival for patients who relapse with Ph+ ALL.
How similar studies have gone: Previous observational and registry studies of Ph+ ALL, particularly those including TKIs, have shown improved outcomes, though detailed profiling of response after relapse remains relatively limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 * Relapse or refractory Ph1 ALL Exclusion Criteria: * none
Where it's running
-
Graall
Pierre-Bénite, France Recruiting
Study contacts
- Study coordinator: Aline SCHMIDT, MD/PhD
- Email: alschmidt@chu-angers.fr
- Phone: 241354482
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combination treatment for BCR-ABL positive B-cell leukemia and chronic myeloid leukemia
This study is testing a new combination treatment for people with BCR-ABL positive B-cell leukemia or chronic myeloid leukemia to see if it helps them feel better and works well with existing medications.
-
Treatment plan for newly diagnosed pediatric Philadelphia chromosome–positive B‑cell acute lymphoblastic leukemia
This Phase 3 effort tests a chemotherapy‑light approach using olverembatinib together with blinatumomab and intermittent venetoclax to see if children and adolescents newly diagnosed with Ph+ B‑ALL can be cured with less toxicity.
-
Low-intensity chemotherapy with olverembatinib, venetoclax and blinatumomab for newly diagnosed Philadelphia chromosome–positive ALL
This trial will test whether adding venetoclax to a low‑intensity chemotherapy plan together with continuous olverembatinib and planned blinatumomab helps people aged 14+ with newly diagnosed Ph+ ALL get deeper early molecular remission and live longer.
-
Evaluating Olverembatinib for Newly Diagnosed Ph+ ALL
This study is testing if a new drug called Olverembatinib, used with chemotherapy, can help people with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia do better than the standard treatment with Imatinib and chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.